Accessing the European medical device market involves more than preparing a single regulatory document. Under the EU Medical Device Regulation, manufacturers need technical documentation and evidence that demonstrate how their device meets regulatory requirements.This makes consistency and traceability particularly important. A technical file may contain extensive information, but problems can still arise when clinical evidence, risk documentation, testing, labelling and post-market records do not tell the same story.

Understanding EU MDR Technical Documentation

EU MDR technical documentation brings together important information about a medical device. This can include device descriptions, specifications, design and manufacturing information, risk management, verification and validation evidence, clinical information, labelling and post-market documentation.

Annex II and Annex III of EU MDR establish key technical documentation requirements. Instead of approaching these areas as separate files, manufacturers should consider how the information connects. For example, a particular device claim may need to be supported consistently through clinical evidence, testing and other documentation.

Why Is GSPR Traceability Important?

General Safety and Performance Requirements, commonly known as GSPR, are another important element of EU MDR compliance. Manufacturers need to determine which requirements apply to their device and demonstrate how conformity with those requirements is supported.

That supporting evidence may involve recognised standards, testing, risk controls, clinical information and other technical records. Clear traceability makes it easier to understand the relationship between a regulatory requirement and the evidence being used to support compliance.

DnA’s EU MDR scope specifically includes technical documentation, design dossier, GSPR, PMS and PMCF support.

Clinical Evidence Cannot Be Viewed in Isolation

Clinical evidence needs to remain connected with other parts of the regulatory documentation. The device’s intended purpose, claims, identified risks and available clinical information should remain consistent.

When one area changes, manufacturers may need to determine whether related documentation also requires an update. This becomes particularly important as additional information becomes available after the device enters the market.

What Happens After Market Entry?

EU MDR responsibilities continue after market access. Post-Market Surveillance, or PMS, provides a structured way to collect and assess information about the device after commercialisation. Where applicable, Post-Market Clinical Follow-up can provide additional clinical information about safety and performance during actual use.

These findings should not remain isolated in a PMS report. Relevant information may need to feed back into risk management, clinical evaluation and other technical documentation.

Why Documentation Remediation May Be Necessary

Existing technical documentation can develop gaps over time. A document may become outdated, evidence may no longer match a claim, or different parts of the technical file may contain conflicting information.

Documentation remediation involves identifying and addressing these inconsistencies. DnA Regulatory Solutions supports EU MDR technical documentation development and remediation, GSPR traceability, clinical evidence and post-market documentation.

Ultimately, strong EU MDR compliance depends on more than having the required documents. Manufacturers need evidence that is organised, traceable and consistent across the device lifecycle.